StockData

Gossamer Bio vs Tenax Therapeutics

GOSS and TENX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GOSS and TENX compare

Gossamer Bio is the larger company, worth 102 times as much as Tenax Therapeutics ($5.4B against $53.1M).

Tenax Therapeutics scores higher on the StockData Score (6 against 1 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGOSSTENX
Size and price
Market cap$5.4B$53.1M
Share price$11.04$1.42
Change, 1 year−94.9%−80.0%
Change, 5 years−98.7%−99.9%
Beta (5Y)2.330.72
Employees16114
StockData Score
Total score16 (better)
Valuation score01 (better)
Growth score1 (better)0
Performance score00
Health score05 (better)
Dividend score00
Valuation
P/S101×–
P/B–0.5×
FCF yield−3.0%–
Growth
Revenue growth (TTM)32.4%–
Profitability
Operating margin−312%–
Net margin−235%–
FCF margin−305%–
Return on equity–−59.8%
Financial health
Debt / equity–0.00
Interest coverage−15.2×–
Current ratio0.5315.07 (better)
Altman Z-score−15.26−1.41 (better)
Piotroski F-score12 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions0.98%81.1%
Held by insiders2.8%4.8%
Insider net buying, 12 months–$6.5M
Superinvestors holding1–
Short interest, % of float0.28%16.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.